The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The study met its primary endpoint and all 11 secondary efficacy endpoints
While Merck can appeal, Halozyme said it expects the order to hold
Subscribe To Our Newsletter & Stay Updated
